TargetMol

Lanreotide

Product Code:
 
TAR-T20534
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T20534-200mg200mg£992.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Lanreotide, a somatostatin analogue, suppresses GH/IGF-I hypersecretion in acromegaly patients. It also used to manage neuroendocrine tumours.
CAS:
108736-35-2
Formula:
C54H69N11O10S2
Molecular Weight:
1096.33
Purity:
0.98
SMILES:
CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)NC(=O)[C@H](N)Cc1ccc2ccccc2c1

References

1. Caplin ME, Pavel M, ?wik?a JB, Phan AT, Raderer M, Sedl??kov? E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P; CLARINET Investigators. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014 Jul 17;371(3):224-33. doi: 10.1056/NEJMoa1316158. PubMed PMID: 25014687. 2. Burness CB, Dhillon S, Keam SJ. Lanreotide autogel(?): a review of its use in the treatment of patients with acromegaly. Drugs. 2014 Sep;74(14):1673-91. doi: 10.1007/s40265-014-0283-8. Review. PubMed PMID: 25193626. 3. Capdevila J, Sevilla I, Alonso V, Ant?n Aparicio L, Jim?nez Fonseca P, Grande E, Reina JJ, Manzano JL, Alonso L?jara JD, Barriuso J, Castellano D, Medina J, L?pez C, Segura ?, Carrera S, Crespo G, Fuster J, Munarriz J, Garc?a Alfonso P. Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis. BMC Cancer. 2015 Jul 4;15:495. doi: 10.1186/s12885-015-1512-6. PubMed PMID: 26138480; PubMed Central PMCID: PMC4490650. 4. Zheng N, Dai W, Zhang H, Wang X, Wang J, Zhang X, Wang K, Li J, Zhang Q. Lanreotide-conjugated PEG-DSPE micelles: an efficient nanocarrier targeting to somatostatin receptor positive tumors. J Drug Target. 2015 Jan;23(1):67-78. doi: 10.3109/1061186X.2014.954118. Epub 2014 Nov 4. PubMed PMID: 25366085.